Business briefs: Everyday Health, Novo Nordisk

Share this article:

Everyday Health said advertising and sponsorship revenue grew 24% last year and that revenue from their top 20 advertisers grew 28%. The health portal said the number of registered consumer users rose to more than 55 million while visits to operated properties grew by 30%. Enhancements to MedPage Today helped bump physician/HCP numbers up 41% and aided an 18% rise in visits overall. Everyday Health launched its food platform and weekly TV series Recipe Rehab—the first YouTube-to-TV show—on ABC last year, and also acquired EQAL, which manages digital content for health and wellness brands and celebs, while expanding their blue-chip investor pool to include Silver Lake Waterman Fund. CEO Ben Wolin forecast “strong double-digit revenue growth” for 2013.

Novo Nordisk received a CRL from the FDA concerning Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart). The CRL said neither drug could be approved in its current form. In the letter, the regulatory body cited a need for additional trials on cardiovascular safety. Novo Nordisk said in a statement they would not have that data prepared for resubmission in 2013. In November of last year, a FDA Advisory committee voted 8:4 to in favor of approval of degludec, with a unanimous decision reached by the panel that Novo should perform a larger clinical trial to examine whether the cardiovascular side effects are a real risk.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.